MEDXF - Medexus and Ethypharm ink a license agreement

Medexus Pharmaceuticals (MEDXF) announces it has entered into an exclusive license agreement with Ethypharm to register and commercialize Triamcinolone Hexacetonide in the U.S.TH is indicated for adults and adolescents for intra-articular, intrasynovial, or periarticular use in the symptomatic treatment of subacute and chronic inflammatory joint diseases, including rheumatoid arthritis.The deal for the 20 mg/mL injectable suspension of the drug requires Medexus to pay an upfront fee along with milestone payments at the time of FDA approval, at commercial product launch, and upon certain sales milestones. Medexus expects to file for FDA approval of TH within 12-24 months.Noting a long-term drug shortage of TH in North America due to previous manufacturing issues, Ken d’Entremont, CEO of Medexus says, “our work with Health Canada prompted the FDA to reach out to us and inquire about the possibility of Medexus providing a similar solution in the United States.’